Targeting the androgen receptor in prostate and breast cancer: Several new agents in development

Endocrine-Related Cancer

Volumn 22, Issue 3, 2015, Pages R87-R106

  Proverbs Singh, Tracy ^a   Feldman, Jarett L ^a   Morris, Michael J ^a,b   Autio, Karen A ^a,b   Traina, Tiffany A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Androgen receptor; Breast cancer; Hormone receptor; Prostate cancer

Indexed keywords

4 [7 [6 CYANO 5 (TRIFLUOROMETHYL) 3 PYRIDINYL] 8 OXO 6 THIOXO 5,7 DIAZASPIRO[3.4]OCTAN 5 YL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; ALISERTIB; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; APATORSEN; APITOLISIB; AZD 3514; BICALUTAMIDE; BUPARLISIB; DACTOLISIB; DASATINIB; ENOBOSARM; ENZALUTAMIDE; FLUTAMIDE; GALETERONE; GANETESPIB; IPATASERTIB; NEW DRUG; NILUTAMIDE; ODM 201; ONALESPIB; ORTERONEL; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VT 464; ANTIANDROGEN; AR PROTEIN, HUMAN;

ANDROGEN SYNTHESIS; ANTIANDROGEN THERAPY; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; MALE; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; BREAST NEOPLASMS; FEMALE; GENETICS; METABOLISM; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR CELL LINE;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84937041191     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0543     Document Type: Review

References (146)

1. Adair FE & Herrmann JB 1946 The use of testosterone propionate in the treatment of advanced carcinoma of the breast. Annals of Surgery 123 1023-1035. (doi:10.1097/00000658-194606000-00006)
2. Agoff SN, Swanson PE, Linden H, Hawes SE & Lawton TJ 2003 Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. American Journal of Clinical Pathology 120 725-731. (doi:10.1309/42F00D0DJD0J5EDT)
3. Andersen R, Mawji N, Wang J, Wang G, Haile S, Myung J, Watt K, Tam T, Yang Y, Bañuelos C et al. 2010 Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17 535-546. (doi:10.1016/j.ccr.2010. 04.027)
4. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL et al. 2014 AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. New England Journal of Medicine 371 1028-1038. (doi:10.1056/NEJMoa1315815)
5. Arce-Salinas C, Riesco-Martinez MC, Hanna W, Bedard P & Warner E 2014 Complete response of metastatic androgen receptor-positive breast cancer to bicalutamide: case report and review of the literature. Journal of Clinical Oncology (In Press). (doi:10.1200/JCO.2013.49.8899)
6. Arslan C, Isik M, Guler G, Kulac I, SolakM, Turker B, Ozisik Y & Altundag K 2012 Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-ERBB-2-positive breast cancer? American Surgeon 78 992-999.
7. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R et al. 2009 Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Research 69 2912-2918. (doi:10.1158/0008-5472.CAN-08-3667)
8. Attard G, de Bono JS, Logothetis CJ, Fizazi K, Mukherjee SD, Joshua AM, Schrijvers D, van den Eertwegh AJ, Li W, Molina A et al. 2015 Improvements in radiographic progression-free survival stratified by ERG gene status in castration-resistant prostate cancer patients treated with abiraterone. Clinical Cancer Research (In Press). (doi:10.1158/1078-0432.CCR-14-1961)
9. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y & Sawyers CL 2013 Overcoming mutationbased resistance to antiandrogens with rational drug design. eLife 2 e00499. (doi:10.7554/eLife.00499)
10. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S et al. 2014 Enzalutamide in metastatic prostate cancer before chemotherapy. New England Journal of Medicine 371 424-433. (doi:10.1056/NEJMoa1405095)
11. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS & Ross SD 1999 Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer and Prostatic Diseases 2 4-8. (doi:10.1038/sj.pcan.4500265)
12. Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno R, Pisani P, Panico S & Secreto G 1996 Serum sex hormone levels after menopause and subsequent breast cancer. Journal of the National Cancer Institute 88 291-296. (doi:10.1093/jnci/88.5.291)
13. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ & Tilley WD 1995 Androgens induce divergent proliferative responses in human breast cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology 52 459-467. (doi:10.1016/0960-0760(95)00005-K)
14. Birrell SN, Hall RE & Tilley WD 1998 Role of the androgen receptor in human breast cancer. Journal of Mammary Gland Biology and Neoplasia 3 95-103. (doi:10.1023/A:1018730519839)
15. Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH & Morgan FJ 1984 Androgen receptors in breast cancer. Cancer 54 2436-2440. (doi:10.1056/NEJMoa1014618)
16. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G & Kallioniemi OP 1999 Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissuemicroarrays. Cancer Research 59 803-806.
17. Caffo O, Palermo A, Veccia A, Maines F, Chierichetti F, Berruti A & Galligioni E 2013 Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer. Urology 82 1090-1093. (doi:10.1016/j.urology.2013.07.029)
18. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H et al. 2011 Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19 575-586. (doi:10.1016/j.ccr.2011.04.008)
19. Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS et al. 2010 Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Research and Treatment 124 607-617. (doi:10.1007/s10549-010-0761-y)
20. Chang C, Saltzman A, Yeh S, Young W, Keller E, Lee HJ, Wang C & Mizokami A 1995 Androgen receptor: an overview. Critical Reviews in Eukaryotic Gene Expression 5 97-125. (doi:10.1615/CritRevEukarGeneExpr. v5.i2.10)
21. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG & Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10 33-39. (doi:10.1038/nm972)
22. Choi JE, Kang SH, Lee SJ & Bae YK 2015 Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Annals of Surgical Oncology 22 82-89. (doi:10.1245/s10434-014-3984-z)
23. Claessens F, Denayer S, Van Tilborgh N, Kerkhofs S, Helsen C & Haelens A 2008 Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nuclear Receptor Signaling 6 e008. (doi:10.1621/nrs.06008)
24. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L et al. 2012 ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Research 72 1494-1503. (doi:10.1158/0008-5472.CAN-11-3948)
25. Cochrane DR, Bernales S, JacobsenBM, CittellyDM, HoweEN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J et al. 2014 Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Research 16 R7. (doi:10.1186/bcr3599)
26. Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ & Tamimi RM 2011 Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Modern Pathology 24 924-931. (doi:10.1038/modpathol.2011.54)
27. Crawford ED, EisenbergerMA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA & Goodman PJ 1989 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New England Journal of Medicine 321 419-424. (doi:10.1056/NEJM198908173210702)
28. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G & Klocker H 1993 Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Molecular Endocrinology 7 1541-1550. (doi:10.1210/mend.7.12.8145761)
29. Dalton JT, Narayanan R & Steiner MS 2013 Selective androgen receptor modulators (SARMs): enobosarm as targeted therapy for the treatment of androgen receptor-positive breast cancer. Cancer Research 73 (Supplement 24) abstract P5-09-21. (doi:10.1158/0008-5472.SABCS13-P5-09-21)
30. D'Amato N, Gu H, Cochrane D, Bernales S, Jacobsen B, Jedlicka P, Torkko K, Edgerton S, Thor A, Elias A et al. 2013 Elucidating the role of AR in breast cancer. Cancer Research 73 (Supplement 8) abstract 4756. (doi:10.1158/1538-7445.AM2013-4756)
31. Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M et al. 2011 TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. European Urology 60 897-904. (doi:10.1016/j.eururo.2011. 07.011)
32. De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A, Lewis MT et al. 2010 Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Research and Treatment 121 1-11. (doi:10.1007/s10549-009-0436-8)
33. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F et al. 2011 Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine 364 1995-2005. (doi:10.1056/NEJMoa1014618)
34. De Wit R, Fizazi K, Jinga V, Efstathiou E, Fong PCC, Wirth M, Suzuki K, Moran S, Wang L, Akaza H et al. 2014 Phase 3, randomized, placebocontrolled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial). Journal of Clinical Oncology 32 (Supplement 15) abstract 5008.
35. Dimitrakakis C & Bondy C 2009 Androgens and the breast. Breast Cancer Research 11 212. (doi:10.1186/bcr2413)
36. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C & Gerald WL 2006 An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25 3994-4008. (doi:10.1038/sj.onc.1209415)
37. Dorgan JF, Stanczyk FZ, Kahle LL & Brinton LA 2010 Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk. Breast Cancer Research 12 R98. (doi:10.1186/bcr2779)
38. Dreicer R, MacLean D, Suri A, Stadler WM, Shevrin D, Hart L, MacVicar GR, Hamid O, Hainsworth J, GrossME et al. 2014 Phase I/II trial of orteronel (TAK-700)-an investigational 17, 20-lyase inhibitor-in patients with metastatic castration-resistant prostate cancer. Clinical Cancer Research 20 1335-1344. (doi:10.1158/1078-0432.CCR-13-2436)
39. Efstathiou E, Titus MA, WenS, SanMiguelA, Hoang A, De Haas-AmatsalehA, Perabo F, Phung D, Troncoso P, Ouatas T et al. 2014 Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology 32 (Supplement 15) abstract 5000.
40. Eisner JR, Abbott DH, Bird IM, Rafferty SW, Moore WR & Schotzinger RJ 2012 VT-464: a novel, selective inhibitor of P450c17(CYP17)-17, 20 lyase for castration-refractory prostate cancer (CRPC). Journal of Clinical Oncology 30 (Supplement 15) abstract e15167.
41. Eliassen AH, Missmer SA, Tworoger SS & Hankinson SE 2006 Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk? Journal of Clinical Oncology 24 1823-1830. (doi:10.1200/JCO.2005.03. 7432)
42. Engelsman E, Korsten CB, Persijn JP & Cleton FJ 1974 Proceedings: oestrogen and androgen receptors in human breast cancer. British Journal of Cancer 30 177. (doi:10.1038/bjc.1974.145)
43. Farmer P, Bonnefoi H, BecetteV, Tubiana-Hulin M, Fumoleau P, LarsimontD, Macgrogan G, Bergh J, Cameron D, Goldstein D et al. 2005 Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24 4660-4671. (doi:10.1038/sj.onc.1208561)
44. Figg WD, Spencer SD, Pisle ST, Pressler HM, Troutman SM, Eisner JR, Rafferty SW, Schotzinger RJ & Moore WR 2012 Activity of oral VT-464, a selective CYP17-lyase inhibitor, in the LNCaP prostate cancer xenograft. Journal of Clinical Oncology 30 (Supplement 15) abstract 4671.
45. Fioretti FM, Sita-Lumsden A, Bevan CL & Brooke GN 2014 Revising the role of the androgen receptor in breast cancer. Journal of Molecular Endocrinology 52 R257-R265. (doi:10.1530/JME-14-0030)
46. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F et al. 2012 Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet. Oncology 13 983-992. (doi:10.1016/S1470-2045(12)70379-0)
47. Fizazi K, Massard C, James N, Culine S, Jones R, Oksala R, Moilanen A, Aho E, Ravanti L & Kallio P 2013 ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: preclinical and phase I data. Journal of Clinical Oncology 31 (Supplement 6) abstract 65.
48. Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, Garcia JA, Protheroe A, Tammela TL, Elliott T et al. 2014 Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet. Oncology 15 975-985. (doi:10.1016/S1470-2045(14)70240-2)
49. Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A et al. 2015 Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. Journal of Clinical Oncology 33 723-731. (doi:10.1200/JCO.2014.56.5119)
50. Ford OH III, Gregory CW, Kim D, Smitherman AB & Mohler JL 2003 Androgen receptor gene amplification and protein expression in recurrent prostate cancer. Journal of Urology 170 1817-1821. (doi:10.1097/01.ju.0000091873.09677.f4)
51. Friedland JC, Smith DL, Sang J, Acquaviva J, He S, Zhang C & Proia DA 2014 Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. Investigational New Drugs 32 14-24. (doi:10.1007/s10637-013-9971-6)
52. Garay JP & Park BH 2012 Androgen receptor as a targeted therapy for breast cancer. American Journal of Cancer Research 2 434-445.
53. Gauthier H, Bousquet G, Pouessel D & Culine S 2012 Abiraterone acetate withdrawal syndrome: does it exist? Case Reports in Oncology 5 385-387. (doi:10.1159/000341564)
54. Gelmann EP 2002 Molecular biology of the androgen receptor. Journal of Clinical Oncology 20 3001-3015. (doi:10.1200/JCO.2002.10.018)
55. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL et al. 2009 Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clinical Cancer Research 15 2472-2478. (doi:10.1158/1078-0432.CCR-08-1763)
56. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A et al. 2013 Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clinical Cancer Research 19 5505-5512. (doi:10.1158/1078-0432.CCR-12-3327)
57. Haapala K, Kuukasjarvi T, Hyytinen E, Rantala I, Helin HJ & Koivisto PA 2007 Androgen receptor amplification is associated with increased cell proliferation in prostate cancer. Human Pathology 38 474-478. (doi:10.1016/j.humpath.2006.09.008)
58. Hara T, Miyazaki J, ArakiH, Yamaoka M, KanzakiN, KusakaM&MiyamotoM 2003 Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Research 63 149-153.
59. He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X & Qin T 2012 Prognostic value of androgen receptor expression in operable triplenegative breast cancer: a retrospective analysis based on a tissue microarray. Medical Oncology 29 406-410. (doi:10.1007/s12032-011-9832-0)
60. He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J, Friedland JC, Sang J, Smith DL, Weigel NL, Wada Y et al. 2013 Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. International Journal of Oncology 42 35-43. (doi:10.3892/ijo.2012.1698)
61. Heath EI, Stein MN, Vaishampayan UN, Antonarakis ES, Liu G, Sheng S, Farrow K, Smith DW & Heilbrun LK 2013 Phase II trial of single-agent ganetespib (STA-9090), a heat shock protein 90 (Hsp90) inhibitor in heavily pretreated patients with metastatic castration-resistant prostate cancer(mCRPC)post docetaxel-based chemotherapy: results of a Prostate Cancer Clinical Trials Consortium (PCCTC) Study. Journal of Clinical Oncology 31 (Supplement 15) abstract 5085.
62. Heinlein CA & Chang C 2004 Androgen receptor in prostate cancer. Endocrine Reviews 25 276-308. (doi:10.1210/er.2002-0032)
63. Heuson JC, Tagnon HJ, Flax H, Salih H, Newton KA & Hobbs JR 1973 Androgen dependence of breast cancers. The Lancet 302 203-204. (doi:10.1016/S0140-6736(73)93035-3)
64. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P et al. 2004 Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. American Journal of Pathology 164 217-227. (doi:10.1016/S0002-9440(10)63112-4)
65. Hong DS, Banerji U, Tavana B, George GC, Aaron J & Kurzrock R 2013 Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treatment Reviews 39 375-387. (doi:10.1016/j.ctrv.2012.10.001)
66. Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, Marotti JD, Hankinson SE, Colditz GA & Tamimi RM 2011 Androgen receptor expression and breast cancer survival in postmenopausal women. Clinical Cancer Research 17 1867-1874. (doi:10.1158/1078-0432.CCR-10-2021)
67. Huggins C, Stephens RE Jr & Hodges C 1941 Studies on prostate cancer II. The effects of castration on advanced carcinoma of the prostate. Archives of Surgery 43 209-223. (doi:10.1001/archsurg.1941. 01210140043004)
68. Isola JJ 1993 Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. Journal of Pathology 170 31-35. (doi:10.1002/path.1711700106)
69. Kelly WK & Scher HI 1993 Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. Journal of Urology 149 607-609.
70. Kennedy BJ 1958 Fluoxymesterone therapy in advanced breast cancer. New England Journal of Medicine 259 673-675. (doi:10.1056/NEJM195810022591404)
71. Key T, Appleby P, Barnes I, Reeves G, Endogenous H & Breast Cancer Collaborative G 2002 Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute 94 606-616. (doi:10.1093/jnci/94. 8.606)
72. Kuhn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis JF, Costa P, Husson JM, Dahan R et al. 1989 Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). New England Journal of Medicine 321 413-418. (doi:10.1056/NEJM198908173210701)
73. Lee HJ & Chang C 2003 Recent advances in androgen receptor action. Cellular and Molecular Life Sciences 60 1613-1622. (doi:10.1007/s00018-003-2309-3)
74. Lehmann BD & Pietenpol JA 2014 Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. Journal of Pathology 232 142-150. (doi:10.1002/path.4280)
75. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y & Pietenpol JA 2011 Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation 121 2750-2767. (doi:10.1172/JCI45014)
76. Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R, Anand A, Lilja H, Heller G, Fleisher M et al. 2009 Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clinical Cancer Research 15 2091-2097. (doi:10.1158/1078-0432.CCR-08-2036)
77. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP & Weeks JC 2012 Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118 5463-5472. (doi:10.1002/cncr.27581)
78. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, GleaveME & Nelson CC 2008 Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Research 68 6407-6415. (doi:10.1158/0008-5472.CAN-07-5997)
79. Loibl S, Muller BM, von Minckwitz G, Schwabe M, RollerM, Darb-Esfahani S, Ataseven B, du Bois A, Fissler-Eckhoff A, Gerber B et al. 2011 Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment 130 477-487. (doi:10.1007/s10549-011-1715-8)
80. Marcelli M, IttmannM, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A et al. 2000 Androgen receptor mutations in prostate cancer. Cancer Research 60 944-949.
81. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN et al. 2013 Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clinical Cancer Research 19 5533-5540. (doi:10.1158/1078-0432.CCR-13-0799)
82. McNamara KM, Moore NL, Hickey TE, Sasano H & Tilley WD 2014 Complexities of androgen receptor signalling in breast cancer. Endocrine-Related Cancer 21 T161-T181. (doi:10.1530/ERC-14-0243)
83. Micello D, Marando A, Sahnane N, Riva C, Capella C & Sessa F 2010 Androgen receptor is frequently expressed in HER2-positive, ER/PRnegative breast cancers. Virchows Archiv 457 467-476. (doi:10.1007/s00428-010-0964-y)
84. Moilanen A, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, Taavitsainen P, Törmäkangas O & Kallio P 2013 ODM-201-new generation antiandrogen with excellent antiandrogenic and antitumor activity in nonclinical models of CRPC. European Journal of Cancer 49 (Supplement 2) abstract 2869. (doi:10.1016/S0959-8049(13)70058-3)
85. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, HiganoCS, True LD & Nelson PS 2008 Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research 68 4447-4454. (doi:10.1158/0008-5472.CAN-08-0249)
86. Morris KT, Toth-Fejel S, Schmidt J, Fletcher WS & Pommier RF 2001 High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy. Surgery 130 947-953. (doi:10.1067/msy.2001.118378)
87. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM et al. 2007 Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castrationresistant prostate cancer. Cancer Research 67 5033-5041. (doi:10.1158/0008-5472.CAN-06-3332)
88. Myung J, Banuelos C, Fernandez J, Mawji N, Wang J, Tien A, Yang Y, Tavakoli I, Haile S, Watt K et al. 2013 An androgen receptor N-terminal domain antagonist for treating prostate cancer. Journal of Clinical Investigation 123 2948-2960. (doi:10.1172/JCI66398)
89. Nantermet PV, Masarachia P, Gentile MA, Pennypacker B, Xu J, Holder D, Gerhold D, Towler D, Schmidt A, Kimmel DB et al. 2005 Androgenic induction of growth and differentiation in the rodent uterus involves the modulation of estrogen-regulated genetic pathways. Endocrinology 146 564-578. (doi:10.1210/en.2004-1132)
90. Narayanan R, Ahn S, Cheney MD, Yepuru M, Miller DD, Steiner MS & Dalton JT 2014 Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling. PLoS ONE 9 e103202. (doi:10.1371/journal.pone.0103202)
91. National Cancer Institute 2013 FDA approval for abiraterone acetate. (http://www.cancer.gov/cancertopics/druginfo/fda-abirateroneacetate)
92. National Comprehensive Cancer Network 2015 Clinical Practice Guidelines in Oncology. Prostate Cancer v1.2015. (http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf)
93. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS & Brown M 2011 Targeting androgen receptor in estrogen receptornegative breast cancer. Cancer Cell 20 119-131. (doi:10.1016/j.ccr.2011. 05.026)
94. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM& Bhargava R 2010 Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Modern Pathology 23 205-212. (doi:10.1038/modpathol. 2009.159)
95. Ogawa Y, Hai E, Matsumoto K, Ikeda K, Tokunaga S, Nagahara H, Sakurai K, Inoue T & Nishiguchi Y 2008 Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. International Journal of Clinical Oncology 13 431-435. (doi:10.1007/s10147-008-0770-6)
96. Osguthorpe DJ & Hagler AT 2011 Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer. Biochemistry 50 4105-4113. (doi:10.1021/bi102059z)
97. O'Shaughnessy J, Campone M, Brain E, Neven P, Hayes DF, Bondarenko I, Griffin TW, Martin JL, De Porre P, Kheoh TS et al. 2014 Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ERC) metastatic breast cancer (MBC). Journal of Clinical Oncology 32 (Supplement 15) abstract 519.
98. Page JH, Colditz GA, Rifai N, Barbieri RL, Willett WC & Hankinson SE 2004 Plasma adrenal androgens and risk of breast cancer in premenopausal women. Cancer Epidemiology, Biomarkers & Prevention 13 1032-1036.
99. Panet-Raymond V, Gottlieb B, Beitel LK, Pinsky L & Trifiro MA 2000 Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Molecular and Cellular Endocrinology 167 139-150. (doi:10.1016/S0303-7207(00)00279-3)
100. Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW & Lee KS 2010 Expression of androgen receptors in primary breast cancer. Annals of Oncology 21 488-492. (doi:10.1093/annonc/mdp510)
101. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL et al. 2009 Androgen receptor inhibits estrogen receptor-α activity and is prognostic in breast cancer. Cancer Research 69 6131-6140. (doi:10.1158/0008-5472.CAN-09-0452)
102. Peters KM, Edwards SL, Nair SS, French JD, Bailey PJ, Salkield K, Stein S, Wagner S, Francis GD, Clark SJ et al. 2012 Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events. BMC Cancer 12 132. (doi:10.1186/1471-2407-12-132)
103. Prostate Cancer Trialists' Collaborative Group 1995 Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346 265-269. (doi:10.1016/S0140-6736(95)92163-X)
104. Prostate Cancer Trialists' Collaborative Group 2000 Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355 1491-1498. (doi:10.1016/S0140-6736(00)02163-2)
105. Rathkopf D, Antonarakis E, Shore N, Tutrone R, Alumkal J, Ryan C, Saleh M, Hauke R, Maneval E & Scher H 2013a ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology 31 (Supplement 6) abstract 48.
106. Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Chow Maneval E, Chen I, Gonen M et al. 2013b Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. Journal of Clinical Oncology 31 3525-3530. (doi:10.1200/JCO.2013.50.1684)
107. Ryan CJ, Smith MR, de Bono JS, MolinaA, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al. 2013 Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine 368 138-148. (doi:10.1056/NEJMoa1209096)
108. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ et al. 2015 Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet. Oncology 16 152-160. (doi:10.1016/S1470-2045(14)71205-7)
109. Safarpour D, Pakneshan S & Tavassoli FA 2014 Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? American Journal of Cancer Research 4 353-368.
110. Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, Wilt TJ & Aronson N 2002 Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95 361-376. (doi:10.1002/cncr.10647)
111. Santagata S, Thakkar A, Ergonul A, Wang B, Woo T, Hu R, Harrell JC, McNamara G, Schwede M, Culhane AC et al. 2014 Taxonomy of breast cancer based on normal cell phenotype predicts outcome. Journal of Clinical Investigation 124 859-870. (doi:10.1172/JCI70941)
112. Sartor AO, Tangen CM, Hussain MH, EisenbergerMA, ParabM, Fontana JA, Chapman RA, Mills GM, Raghavan D, Crawford ED et al. 2008 Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 112 2393-2400. (doi:10.1002/cncr.23473)
113. Scher HI & Heller G 2000 Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 55 323-327. (doi:10.1016/S0090-4295(99)00471-9)
114. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R et al. 2008 Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology 26 1148-1159. (doi:10.1200/JCO.2007.12.4487)
115. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J et al. 2010 Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375 1437-1446. (doi:10.1016/S0140-6736(10)60172-9)
116. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND et al. 2012 Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine 367 1187-1197. (doi:10.1056/NEJMoa1207506)
117. Scher HI, Fizazi K, Saad F, Chi KN, Taplin ME, Sternberg CN, Armstrong AJ, Hirmand M, Forer D & De Bono JS 2013 Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor. Journal of Clinical Oncology 31 (Supplement 6) abstract 6.
118. Schwartzberg L, Yardley D, Elias A, Patel M, Gucalp A, Burris H, Peterson A, Hannah A, Blaney M, Gibbons J et al. 2014 Enzalutamide plus exemestane: a pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer. Journal of Clinical Oncology 32 (Supplement 15) abstract 545.
119. Shapiro GI, Kwak EL, Dezube BJ, Yule M, Ayrton J, Lyons J & Mahadevan D 2015 First-in-human phase 1 dose escalation study of a secondgeneration non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors. Clinical Cancer Research 21 87-97. (doi:10.1158/1078-0432.CCR-14-0979)
120. Small EJ & Carroll PR 1994 Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43 408-410. (doi:10.1016/0090-4295(94)90092-2)
121. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E & Vogelzang NJ 2004 Antiandrogen withdrawal alone or in combination with ketoconazole in androgenindependent prostate cancer patients: a phase III trial (CALGB 9583). Journal of Clinical Oncology 22 1025-1033. (doi:10.1200/JCO. 2004.06.037)
122. Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore N, Liu G, Alumkal JJ, Higano CS, Chow Maneval E & Rathkopf DE 2013 ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology 31 (Supplement 6) Abstract 7.
123. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG & Balk SP 2006 Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Research 66 2815-2825. (doi:10.1158/0008-5472.CAN-05-4000)
124. Taipale M, Jarosz DF & Lindquist S 2010 HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nature Reviews. Molecular Cell Biology 11 515-528. (doi:10.1038/nrm2918)
125. Takeda Pharmaceutical Company Limited 2014 Takeda announces termination of orteronel (TAK-700) development for prostate cancer in Japan, U.S.A. and Europe. (http://www.takeda.com/news/2014/20140619-6615.html)
126. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE et al. 1997 Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Molecular Endocrinology 11 450-459. (doi:10.1210/mend.11.4.9906)
127. Tang D, Xu S, Zhang Q & Zhao W 2012 The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Medical Oncology 29 526-533. (doi:10.1007/s12032-011-9948-2)
128. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ et al. 2003 Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study. Journal of Clinical Oncology 21 2673-2678. (doi:10.1200/JCO.2003.11.102)
129. Taplin ME, Chu F, Morrison JP, Pili R, Rettig MB, Stephenson J, Vogelzang NJ & Montgomery RB 2012 ARMOR1: safety of galeterone (TOK-001) in a phase 1 clinical trial in chemotherapy naïve patients with castration resistant prostate cancer (CRPC). Cancer Research 72 (Supplement 8) CT-07. (doi:10.1158/1538-7445.AM2012-CT-07)
130. Taplin ME, Montgomery RB & ARMOR2Group 2014 ARMOR2: galeterone in progressive CRPC patients who have failed oral therapy. Journal of Clinical Oncology 32 (Supplement 4) abstract 71.
131. Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME & Zoubeidi A 2013 Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Molecular Cancer Therapeutics 12 2342-2355. (doi:10.1158/1535-7163.MCT-13-0032)
132. Titus MA, Schell MJ, Lih FB, Tomer KB & Mohler JL 2005 Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clinical Cancer Research 11 4653-4657. (doi:10.1158/1078-0432.CCR-05-0525)
133. Tokunaga E, Hisamatsu Y, Taketani K, Yamashita N, Akiyoshi S, Okada S, Tanaka K, Saeki H, Oki E, Aishima S et al. 2013 Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer. Cancer Medicine 2 763-773. (doi:10.1002/cam4.138)
134. Toren PJ, Kim S, Pham S, Mangalji A, Adomat H, Guns ES, Zoubeidi A, Moore W & Gleave ME 2015 Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer. Molecular Cancer Therapeutics 14 59-69. (doi:10.1158/1535-7163.MCT-14-0521)
135. Traina T, O'Shaughnessy J, Kelly C, Schwartzberg L, Gucalp A, Peterson A, Bhattacharya S, Trudeau M, Hudis C & Schmid P 2013 A phase 2 singlearm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer. Cancer Research 73 (supplement 24) OT3-2-08. (doi:10.1158/0008-5472.SABCS13-OT3-2-08)
136. Traina T, O'Shaughnessy J, Nanda R, Schwartzberg L, Abramson V, Cortes J, Peterson A, Tudor I, BlaneyM, Steinberg J et al. 2014 Stage 1 results from MDV3100-11: a 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced ARC triple-negative breast cancer (TNBC). 2014 San Antonio Breast Cancer Symposium, San Antonio, TX, USA, December 9-13, 2014. Abstract P5-19-09.
137. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A et al. 2009 Development of a secondgeneration antiandrogen for treatment of advanced prostate cancer. Science 324 787-790. (doi:10.1126/science.1168175)
138. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J & Kallioniemi OP 1995 In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics 9 401-406. (doi:10.1038/ng0495-401)
139. Vranic S, Gatalica Z & Wang ZY 2011 Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies. Oncology Letters 2 1131-1137. (doi:10.3892/ol.2011.375)
140. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Janne OA & Visakorpi T 2009 Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Research 69 8141-8149. (doi:10.1158/0008-5472.CAN-09-0919)
141. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K & Sawyers CL 2010 Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require fulllength androgen receptor. PNAS 107 16759-16765. (doi:10.1073/pnas. 1012443107)
142. Witzel I, GraeserM, KarnT, SchmidtM, WirtzR, SchutzeD, RauschA, JanickeF, Milde-Langosch K & Muller V 2013 Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers. Journal of Cancer Research and Clinical Oncology 139 809-816. (doi:10.1007/s00432-013-1382-8)
143. Wong YC & Xie B 2001 The role of androgens in mammary carcinogenesis. Italian Journal of Anatomy and Embryology 106 111-125.
144. Xie B, Tsao SW & Wong YC 1999 Sex hormone-induced mammary carcinogenesis in female noble rats: the role of androgens. Carcinogenesis 20 1597-1606. (doi:10.1093/carcin/20.8.1597)
145. Yamaoka M, Hara T, Araki H, Kaku T, Hitaka T, Tasaka A & Kusaka M 2013 Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen-and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys. Journal of Steroid Biochemistry and Molecular Biology 138 298-306. (doi:10.1016/j.jsbmb.2013.07.002)
146. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM & Feldman D 2000 Glucocorticoids can promote androgenindependent growth of prostate cancer cells through a mutated androgen receptor. Nature Medicine 6 703-706. (doi:10.1038/76287)